Biolase (BIOLQ) 8-K Regulation FD Disclosure

Fred Furry, CFO

October 4, 2012

Nasdaq: BIOL

PAGE 1

Exhibit 99.1

The BIOLASE

Total Solution

The BIOLASE

Total Solution

Safe Harbor Statement

PAGE 2

This presentation may contain forward-looking statements that are based on our current expectations, estimates and

projections about our industry as well as management’s beliefs and assumptions. Words such as “anticipates,” “expects,”

“intends,” “plans,”  “believes,”  “seeks,” “estimates,” “may,” “will,” and variations of these words or similar expressions are

intended to identify forward-looking statements. These statements include projections about our future earnings and

margins and speak only as of the date hereof. Such statements are based upon the information available to us now and

are subject to change. We will not necessarily inform you of such changes. These statements are not guarantees of future

performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Therefore our

actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of

various factors. The important factors which could cause actual results to differ materially from those in the forward-looking

statements include, among others, a downturn or leveling off of demand for our products due to the availability and pricing

of competing products and technologies, adverse international market or political conditions, a domestic economic

recession, the volume and pricing of product sales, our ability to control costs, intellectual property disputes, the effects of

natural disasters and other events beyond our control and other factors including those detailed in BIOLASE’s filings with

the Securities and Exchange Commission including its prior filings on Form 10-K and 10-Q.

Conventional Surgical Devices include the scalpel, high

speed drill, electrosurge, electric bone saws, and heat

generating lasers.

PAGE 3

What is Waterlase?

BIOLASE has invented an optimized a biological method to cut tissue.

Waterlase

is

a

bilogical

method

to

cut

tissue

with

little

trauma

or

bleeding.

The energy from our laser interacts with the water molecules within tissue,

the absorption of our laser energy expands and vaporizes the water

molecules causing a biological ablation with very little trauma or bleeding.

The BIOLASE

Total Solution

BIOLASE is Revolutionizing Surgery in Dentistry and

      Medicine Through the Science of Waterlase

•

BIOLASE is a medical technology company that develops, manufactures,

and markets dental lasers.

•

BIOLASE also markets and distributes dental imaging equipment, intra-

oral scanners, and other products designed for procedures in dentistry

and medicine.

•

2011 GAAP revenue of $48.9 million, up 87% from 2010.

•

2011 Adjusted Non-GAAP revenues up 98% from 2010.

•

2012 Adjusted Non-GAAP revenue guidance of $57 to $60 million. 

The midpoint of our guidance of $58.5 million represents an increase of

36% from 2011, excluding equipment sales to Henry Schein for the

repayment of a liability of $5.9 million in 2011.

PAGE 4

BIOLASE:

Company

Overview

The BIOLASE

Total Solution

BIOLASE: Key Milestones

1998

FDA clearance received for all-tissue Waterlase technology; began selling Waterlase.

2004

Introduced the ezLase, our first soft-tissue diode laser.

2006

Released the Waterlase MD Turbo, a significant advance in our technology.

2006

Entered into exclusive distribution agreement with Henry Schein.

2010

Introduced the handheld, battery operated iLase soft tissue diode laser.

2011

Introduced the revolutionary Waterlase iPlus, which equaled the speed of a high-speed dental drill;

Sales

double

from

2010

under

the

guidance

of

Federico

Pignatelli

and

reinstituted

direct sales

model; Introduced BIOLASE DaVinci Imaging products.

2012

Final separation from Schein;

Introduced the Waterlase MDX line of all-tissue lasers; 

Introduced the EPIC 10 soft tissue diode laser, a platform for additional diode lasers;

CE Mark received for EPIC 10 in final days of Q3 2012 and FDA approval received in October

2012; Entered into agreements to distribute Cefla’s New Tom CBCTs and 3Shape’s Trios intra-oral

scanner.

PAGE 5

The BIOLASE

Total Solution

Chart & Financial History

1994-Aug 2006 Pignatelli

Chairman of the Board

Exclusive distribution

partnership with Henry Schein

Aug 2006–Aug 2010

Aug 2010 to present

Pignatelli Chairman of the

Board and CEO

Aug 2010

Pignatelli

Reinstated

Chairman

FDA

Clearance

Rec’d for

Waterlase

in 1998

$20

$15

$10

$5

PAGE 6

The BIOLASE

Total Solution

Traditional Dentistry

Cavadenti, The Tooth Puller, by Caravaggio, circa 1608

PAGE 7

The BIOLASE

Total Solution

BIOLASE: the World Leader in Laser Dentistry

Atraumatic Pediatric Tooth Extraction             

The aiming beam on

the Waterlase does

not cut the tissue or

generate any heat. 

The tissue is cut

biologically, with little

or no pain, by

energizing water at

the molecular level.

…with over 20,000 lasers sold worldwide, including our revolutionary Waterlase iPlus, which was

launched in Q1 2011:

The iPlus features an

intuitive, touch-based

computer screen,

similar to a tablet

personal computer. 

It is designed to

allow for remote

servicing and

software upgrades.

PAGE 8

The BIOLASE

Total Solution

Digital

Imaging:

We

offer

Cefla’s

NewTom

cone

beam

3D

imaging

and

a

full

line of BIOLASE DaVinci Imaging equipment, including the D3D CBCT. 

We also distribute 3Shape’s Trios intra-oral scanning device for digital

impression-taking solutions.

Diode

soft-tissue

dental

lasers:

Our

soft

tissue

lasers

include

the revolutionary iLase, a portable diode laser with no foot

pedal, power cord, or external controls, and the newly

launched & FDA cleared EPIC 10, our total diode solution.

Current Line of BIOLASE Products

All-tissue dental lasers:

Our all-tissue lasers include our flagship laser, the revolutionary

Waterlase iPlus, and the new Waterlase MDX 450 and 300.

PAGE 9

Medical:

Our

diode

laser

technology

offers

high

intensity

laser

therapy

in

the palm of your hand for pain management.

The BIOLASE

Total Solution

How It Works: Waterlase High Speed Cutting 

PAGE 10

The BIOLASE

Total Solution

Waterlase: Side by Side with Drill

PAGE 11

The BIOLASE

Total Solution

The BIOLASE

Total Solution

Waterlase: Soft Tissue Lingual Frenectomy

PAGE 12

$50B to $100B Waterlase Market Opportunity

Global market opportunity is immense…because the dental

community is the largest medical community in the world.

•

176,000

dentists

in

the

US

and

Canada.

¹

•

Over 1.2 million dentists in 134 countries and growing

rapidly

in

emerging

economies.

²

•

Over 20,100 systems in over 16,000 practices.

•

Every incremental 1% of market penetration, just with the

Waterlase, is equal to an opportunity of well over $600

million in revenues

Estimated total global market of 1,200,000,

which is growing rapidly due to new markets

(e.g., China, India, and Indonesia).

Over

20,100

³

systems

sold

worldwide.

1. American Dental Association.  2. World Federation of Dentistry.  3. 1998-present over 20,100 BIOLASE systems sold.

Our market penetration is approximately 5% of dental

practices in the US and approximately 1% internationally.

PAGE 13

The BIOLASE

Total Solution

BIOLASE’s Dominant Market Position

Owning BIOLASE means owning the hard-tissue dental laser market…

80% BIOLASE

Source: BIOLASE Technology Licensing Reports

PAGE 14

The BIOLASE

Total Solution

Source: iData Research Inc.

BIOLASE’s Dominant Market Position

…and the overall dental laser market.

PAGE 15

45% BIOLASE

The BIOLASE

Total Solution

Current

Status:

BIOLASE

has

a

tremendous

IP

portfolio

with

over

290

issued

and

pending patents, 70% of which are related to our core Waterlase (Er,Cr:YSGG)

technology and medical lasers.

•

Filing and maintenance costs are closely monitored.

•

Funding for redundant patents / patents with a low-probability for issuance is stopped.

BIOLASE’s Extensive Patent Portfolio

Issued &

Active

Pending

Total

U.S.

81

52

133

International

81

77

158

Total

162

129

291

PAGE 16

The BIOLASE

Total Solution

How Waterlase is Changing Dentistry

Pain free in many cases:

•

With no anesthesia, Waterlase increases efficiency and allows the dentist to work in multiple

quadrants in a single visit.

Less damage to the surrounding tissue.

Speed

of

Waterlase

now

matches

a

high-speed

drill,

for

the

first

time

since

introduced.

New standard of care:

•

Reinvigorates the dentist, their patients, and the practice.

Virtually eliminates the high risk of cross contamination from dental drills.

Increases acceptance for procedures, including those not performed with a dental drill.

High ROI:

•

Can equate to $250-$750 of additional DAILY revenue: gingivectomy is $160; perio treatment is

$375; hard-tissue crown lengthening is $520; herpetic or aphthous ulcer is $308; and a

frenectomy is $355.

•

Procedures are easy to learn and training is included in the cost.

PAGE 17

The BIOLASE

Total Solution

Waterlase MD ™

reduced  E. faecalist 2.86

times more effectively than NaOCl³

Burs and Endo Files:

•

15% of “sterilized”

burs and up to 76% of “sterilized”

endodontic

files

carry

pathogenic

micro-organisms.

•

Complex and rugged bur surface difficult to sterilize.

•

Autoclaving

fails

15%

of

the

time

to

decontaminate

burs.

•

Only 32% of endodontic engine-driven files are replaced after

every

case

and

36%

after

every

other

case.

Waterlase Tips:

•

Smooth tip surface does not harbor debris or bacteria

like the abrasive surfaces of burs or files.

•

YSGG

laser

energy

is

bacteriacidal.

3

•

Single-use, disposable tips that work without the need

to contact tissue. 

•

Eliminates accidental sticks with contaminated burs.

BIOLASE’S Waterlase technology essentially eliminates the risk of cross contamination and contagion:

Eliminating the Risk of Cross Contamination

PAGE 18

The BIOLASE

Total Solution

1, 2

4

1. Dental Burs and Endodontic Files: Are Routine Sterilization Procedures Effective?: Archie Morrison, DDS, MS, FRCD(C); Susan Conrod, DDS JCDA • www.cda-adc.ca/jcda • February 2009, Vol. 75, No. 1.  2. Contaminated dental

instruments: Smith A, Dickson M, Aitken J, Bagg J.J Hosp Infect. 2002 Jul;51(3):233-5.  3. The antimicrobial efficacy of the erbium, chromium:yttrium-scandium-gallium-garnet laser with radial emitting tips on root canal dentin

walls infected with Enterococcus faecalis: Wanda Gordon, DMD, Vahid A. Atabakhsh, DDS, Fernando Meza, DMD, Aaron Doms, DDS, Roni Nissan, DMD, Ioana Rizoiu, MS and Roy H. Stevens, DDS, MS JADA 2007; 138(7): 992-1002

4. Dentaltown Research: Endodontics; Survey, October 2011, dentaltown.com.

1

Patented laser toothbrush for home use:

•

Development underway with The Proctor and Gamble Company to develop a laser

toothbrush

for

home

use

that

has

the

capability

to

whiten

teeth,

disinfect

teeth

and

gums,

bio-stimulate teeth and gums, and relieve pain. 

New lasers:

•

February 2012: Introduced the Waterlase MDX line of all-tissue lasers with plans to continue

to offer additional complimentary all-tissue Waterlase products.

•

April 2012: Introduced the EPIC 10 soft-tissue laser.  International sales initiated in

September 2012 and FDA clearance received in October 2012. 

New Imaging products:

•

February 2012: BIOLASE became the exclusive North American distributor for Cefla’s

NewTom cone beam 3D imaging products, which complements our large family of BIOLASE

DaVinci Imaging products.

•

August 2012: BIOLASE became a distributor of 3Shape’s Trios intra-oral scanning

technologies.

PAGE 19

The BIOLASE

Total Solution

Pursuing More Opportunities to Expand in Dentistry

With our patented Waterlase and diode technologies, we have

created

technological

platforms

that

have

the

ability

to

extend

beyond dentistry:

Ophthalmology:

We

hold

14

issued

and

19

pending

U.S.

and

International

patents

in

four patent families in the field of ophthalmology, giving us a wide range of

applications

and

coverage.

Capability

to

restore

the

elasticity

of

the

eye

and

allow

it to return to normal function, eliminating presbyopia.  We expect approval to

market

our

patented

Waterlase

technology

for

glaucoma,

dry

eyes,

and

presbyopia

in the next several years.

Orthopedics:

We

are

working

with

several

key

manufacturers

and

universities

to

provide solutions that are not currently available.  We are investigating

opportunities

for

several

orthopedic

applications

and

anticipate

filing

several

510(k)

applications during 2012 and 2013.

Opportunities to Expand Beyond Dentistry 

PAGE 20

The BIOLASE

Total Solution

We expect to expand our addressable markets in 2012 and 2013;

these

potential

markets

represent

multi-billion

dollar

opportunities.

Aesthetics:

We have various FDA approvals for applications in oculoplastics,

dermatology, and plastic surgery, and are currently investigating options for entering

these markets in 2012 and 2013.

Pain

Management:

We

anticipate

launching

a

new

deep-tissue

hand

piece

and

upgraded diode laser for pain therapy in 2012, which will coincide with a new

marketing campaign.  Pain therapy works and we are seeing more high-level

athletes seeking treatment.

Podiatry:

We

have

found

that

our

diode

laser

technology

is

also

very

effective

in

the

treatment of nail fungus and we are completing the clinical and regulatory

requirements necessary to enter the market in late 2012/early 2013.

Opportunities

to

Expand

Beyond

Dentistry

(Continued)

PAGE 21

The BIOLASE

Total Solution

BIOLASE Today

Company Headquarters in Irvine, California

•

Over 190 employees worldwide.

•

Sales offices in Floss (Germany), Madrid (Spain), Shanghai

(China), and Mumbai (India), with expansion planned in Dubai

(UAE), and Rio de Janero (Brazil). 

•

Floss also has service and manufacturing capabilities.

•

Our new state-of-the-art training facilities are located in Irvine, CA.

BIOLASE Europe in Floss, Germany

•

Corporate HQ in Irvine, California

•

57,000 sq. ft. facility houses finance & administrative, sales,

marketing, customer care, training, manufacturing, and R&D.

•

Can accommodate growth to $250 million.

•

ISO 9001 certified and FDA GMP with white-room operations.

PAGE 22

The BIOLASE

Total Solution

Investment Considerations

PAGE 23

•

Ongoing growth in sales and core product line under new distribution model

•

Addressing $50B-100B market opportunity

•

Growth drivers include:

•

Strong IP portfolio with additional patents pending

•

Strengthened financial situation

•

CEO’s interests aligned with stockholders

The BIOLASE

Total Solution

–

Market leader in laser dentistry

–

Significant potential market opportunities beyond core dental focus

–

Product improvements and product diversification

–

Expansion

into

new

markets,

with

small

investments

necessary

for

proof

of

concepts

(approximately $2 million)

–

Performance-based culture